Form 4 Neuropace Inc For: 22 September
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neuropace Inc (NPCE)
Neuropace Inc stock price live, this page displays NASDAQ NPCE stock exchange data. View the NPCE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neuropace Inc real time stock price chart below.
What Is the Neuropace Inc Stock Price Today?
The Neuropace Inc stock price today is 12.70.
What Is the Stock Symbol for Neuropace Inc?
The stock ticker symbol for Neuropace Inc is NPCE.
Is NPCE the Same as $NPCE?
$NPCE is a common way to refer to the Neuropace Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Neuropace Inc Trade On?
Neuropace Inc is listed and trades on the NASDAQ stock exchange.
Is Neuropace Inc a Good Stock to Buy?
Determining whether Neuropace Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Neuropace Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NPCE quote. (ISIN: US6412881053)
What Is the Neuropace Inc Stock Price Today?
The Neuropace Inc stock price today is 12.70.
What Is the Stock Symbol for Neuropace Inc?
The stock ticker symbol for Neuropace Inc is NPCE.
Is NPCE the Same as $NPCE?
$NPCE is a common way to refer to the Neuropace Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Neuropace Inc Trade On?
Neuropace Inc is listed and trades on the NASDAQ stock exchange.
Is Neuropace Inc a Good Stock to Buy?
Determining whether Neuropace Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Neuropace Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NPCE quote. (ISIN: US6412881053)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.68
13.34
52 wk Range
9.22
19.60
NPCE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.6813.34
52 wk Range
9.2219.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NPCE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
20.00
Upside
+57.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Neuropace receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 4 Neuropace Inc For: 22 September
- Investing.com
- Neuropace receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.00
(+57.48% Upside)
Neuropace Inc SWOT Analysis
Analyst Projections | Bullish outlook with price targets ranging from $15 to $20, suggesting significant upside potential in the $1.4 billion addressable domestic market |
Market Expansion Plans | Explore NeuroPace's strategies to double its addressable market through expanded indications and increased penetration into community settings |
Financial Performance | Strong revenue growth with a 22% year-over-year increase and a robust five-year CAGR of 17%, maintaining a 74.8% gross profit margin |
Innovative Epilepsy Tech | NeuroPace's RNS System shows superior efficacy in treating drug-resistant focal epilepsy, positioning the company as a leader in neurostimulation technology |
Neuropace Inc Earnings Call Summary for Q2/2026
- NeuroPace Q2 2026 revenue rose 17% YoY to $22.83M, beating estimates; adjusted loss of $0.18/share narrower than expected $0.21 loss.
- Company raised FY2026 revenue guidance to $99.5M-$101.5M and improved adjusted EBITDA loss forecast to $7.5M-$8.5M from $8.5M-$9.5M.
- RNS System sales grew 21.3% to $22.5M; management expects Q3 growth of ~20% YoY with potential H2 acceleration to 20%-25%.
- Shares fell 3.65% after hours despite beat as investors focused on ongoing losses and regulatory uncertainty around IGE program FDA approval.
- CEO highlighted AI-driven ECoG Assistant tool launch; remote-care FDA submission expected by end-2026, cash flow breakeven targeted exiting 2027.
Last Updated: 08/11/2026, 05:42 PM
Read Full TranscriptNeuropace investor slides for Q2/2026
Last Update: Aug 11, 2026
See full investor slides
Earnings
Latest Release
Aug 11, 2026
EPS / Forecast
-0.18 / -0.21
Revenue / Forecast
22.83M / 22.56M
Compare NPCE to Peers and Sector
Metrics to compare | NPCE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNPCEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −27.0x | −4.1x | −0.3x | |
PEG Ratio | −0.84 | −0.11 | 0.00 | |
Price / Book | 36.7x | 2.5x | 2.6x | |
Price / LTM Sales | 4.1x | 2.0x | 3.0x | |
Upside (Analyst Target) | 57.5% | 141.2% | 58.6% | |
Fair Value Upside | Unlock | 10.2% | 8.4% | Unlock |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Neuropace (NPCE) Stock Price Today?
The Neuropace stock price today is 12.70 USD.
What Stock Exchange Does Neuropace Trade On?
Neuropace is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Neuropace?
The stock symbol for Neuropace is "NPCE."
What Is the Neuropace Market Cap?
As of today, Neuropace market cap is 451.36M USD.
What Is Neuropace's Earnings Per Share (TTM)?
The Neuropace EPS (TTM) is -0.48.
When Is the Next Neuropace Earnings Date?
Neuropace will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is NPCE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Neuropace Stock Split?
Neuropace has split 0 times.
How Many Employees Does Neuropace Have?
Neuropace has 220 employees.
What is the current trading status of Neuropace (NPCE)?
As of Oct 03, 2026, Neuropace (NPCE) is trading at a price of 12.70 USD, with a previous close of 13.15 USD. The stock has fluctuated within a day range of 12.68 USD to 13.34 USD, while its 52-week range spans from 9.22 USD to 19.60 USD.
What Is Neuropace (NPCE) Price Target According to Analysts?
The average 12-month price target for Neuropace is 20.00 USD, with a high estimate of 22 USD and a low estimate of 18 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +57.48% Upside potential.
What Is the NPCE Premarket Price?
NPCE's last pre-market stock price is 13.34 USD. The pre-market share volume is 12.00, and the stock has decreased by 0.19, or 1.44%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.